Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer - KIVIRID

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer

Authors: Peter Paul Yu, Omar Eton, Louis P. Garrison

Published: 2019-09-03

DOI: 10.1186/s40425-019-0707-9

Source: Full article

Abstract

No abstract found.